Journal
The science of Akkermansia, in plain English.
Why we don't make claims (and why that's the point)
Most supplement brands promise outcomes. We describe research and stop there. Here's the EU rulebook behind that choice — and why restraint, not bravado, is the strategy we chose on purpose.
Urolithin A, explained
Your body can't make urolithin A on its own. Your gut microbes make it from the polyphenols in pomegranate and berries. Here's what it is, how it's made, and what the human trials actually show.
The mucin layer: your gut's quiet workhorse
The mucus lining your gut is a two-layer barrier that quietly keeps the inside in. Here's how it works, how Akkermansia helps renew it, and why a healthy barrier matters.
The mouse study that started a field
In 2013, one mouse study turned an obscure gut bacterium into a research field. Here's what Everard and colleagues found — and the metformin clue that arrived alongside it.
Raspberry and the gut barrier: the everyday one
The gentlest member of the range, built around the gut's mucus lining — where Akkermansia lives, and what it's named for. An honest look at a thinner but real evidence base.
The pomegranate trail: from a Mediterranean fruit to a mitochondrial molecule
Pomegranate → Akkermansia → urolithin A. One of the most carefully traced food-to-microbe-to-metabolite pathways in nutrition science, and the reason pomegranate anchors our longevity pairing.
From a Belgian lab to your doorstep: how we source
Three ingredients, traced honestly: the bacterium from the European lab holding the EU Novel Food authorisation, freeze-dried European berries, and no preservatives. Here's the chain.
How freeze-drying works (and why space agencies use it)
Freeze-drying removes water without heat damage, which is exactly why it suits a pasteurised bacterium whose value lives in its surface proteins. Here's the physics, plainly.
Bilberry: the metabolic berry
Why we paired Akkermansia with the wild European bilberry — the small dark berry with two to four times the anthocyanins of a cultivated blueberry, and a place in the metabolic-health literature.
Amuc_1100: the protein doing the work
A single outer-membrane protein from Akkermansia reproduces much of the whole bacterium's effect in mice — which neatly explains why the dead, pasteurised form works at all.
Akkermansia and type 2 diabetes: the 2025 trial in context
In 2025, a human trial extended the Akkermansia research into people with type 2 diabetes. Here's what it found, how it builds on a 2019 proof-of-concept, and why we describe it carefully.
Akkermansia and the immune system: an honest look
Akkermansia keeps appearing in immune research, including a landmark 2018 cancer-immunotherapy study. It's a fascinating, exploratory association — and explicitly not a claim that our supplement does anything to immunity.
What is Akkermansia muciniphila?
A gut bacterium discovered in 2004, named for the mucus layer it lives in — and one of the most-studied microbes in modern metabolic and longevity science.
The pasteurised paradox: why dead bacteria worked better than live ones
In the first human trial of Akkermansia, the pasteurised form outperformed the live one. Here's why non-living bacteria can be the more useful kind — and why the EU authorised exactly that form.
The protein, the receptor, the hormone: Akkermansia and GLP-1
GLP-1 is the hormone behind today's biggest metabolic conversation. In 2021, scientists found that Akkermansia secretes a specific protein that triggers your gut to release it. This is mechanism, not metaphor.